• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Aduhelm

Could I be wrong? Exploring cognitive bias, curiosity, intellectual humility, and lifelong learning

November 30, 2021 by SharpBrains

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing eight time­ly sci­en­tif­ic and indus­try news plus a few fun teasers to appre­ci­ate our unique human brains.

#1. Could I be wrong? Explor­ing research on cog­ni­tive bias, curios­i­ty, intel­lec­tu­al humil­i­ty, and life­long learning

“None of us thinks that our beliefs and atti­tudes are incor­rect; if we did, we obvi­ous­ly wouldn’t hold those beliefs and atti­tudes. Yet, despite our sense that we are usu­al­ly cor­rect, we must accept that our views may some­times turn out to be wrong. This kind of humil­i­ty isn’t sim­ply virtuous—the research sug­gests that it results in bet­ter deci­sions, rela­tion­ships, and out­comes. So, the next time you feel cer­tain about some­thing, you might stop and ask your­self: Could I be wrong?”

#2. Great inter­view on bilin­gual­ism, sports, edu­ca­tion and neu­ro­plas­tic­i­ty — en español

#3. Should old­er politi­cians, and oth­er lead­ers, under­go cog­ni­tive test­ing? The debate con­tin­ues … here are some good com­ments from the online debate we had last summer:

  • PRO: “Def­i­nite­ly. We rou­tine­ly screen appli­cants for a wide range of jobs. Apply for the police, you will be test­ed. Join the mil­i­tary, you will be eval­u­at­ed. Should we not know if a can­di­date for the high­est posi­tion in the coun­try has a seri­ous emo­tion­al, intel­lec­tu­al or psy­cho­log­i­cal impairment?”
  • CON: “I dis­agree because these tests are very bad at pre­dict­ing how good some­one would be in lead­ing a coun­try. It doesn’t require the abil­i­ty to store a lot of infor­ma­tion in your work­ing mem­o­ry. Being a good leader requires only one essen­tial thing: hav­ing the right priorities.”
  • IT DEPENDS: “Who makes the test? What cog­ni­tive met­rics do we use? The bias­es in that design could lead to sig­nif­i­cant unex­pect­ed or even inten­tion­al­ly skewed results.”

#4. Click Ther­a­peu­tics rais­es fur­ther $52M to build up dig­i­tal ther­a­peu­tics pipeline for depres­sion, insom­nia, smok­ing ces­sa­tion and more

What a year for Click and for dig­i­tal therapeutics!

#5. The Amer­i­can Med­ical Association’s (AMA) to ease access to remote Cog­ni­tive Behav­ioral Ther­a­py Monitoring

The road to heav­en is paved with good decisions…

#6. FDA-approved, Cybin-spon­sored clin­i­cial tri­al to mea­sure ketamine’s impact on the brain via Ker­nel Flow neu­roimag­ing helmet

“The word psy­che­del­ic means ‘mind-man­i­fest­ing,’ but what has been miss­ing is use­ful ‘mind-imaging’—the abil­i­ty to dynam­i­cal­ly trace the neur­al cor­re­lates of human con­scious expe­ri­ence. Con­ven­tion­al neu­roimag­ing just isn’t dynam­ic enough to study the psy­che­del­ic expe­ri­ence in the brain as it hap­pens. This study of ketamine’s psy­che­del­ic effects while wear­ing head­gear equipped with sen­sors to record brain activ­i­ty could open up new fron­tiers of under­stand­ing” — Dr. Alex Belser, Cybin’s Chief Clin­i­cal Officer

#7. Bea­con Biosig­nals rais­es $27M to scale EEG, AI-based neu­ro­bio­mark­er dis­cov­ery platform

“ana­lyz­ing EEGs is labor inten­sive and inter­pre­ta­tion of these tests can vary from one clin­i­cian to another..…Beacon Biosig­nals has assem­bled what it claims is one of the world’s largest clin­i­cal EEG data­bas­es. By apply­ing its pro­pri­etary machine-learn­ing algo­rithms to the data­base, the com­pa­ny says it has iden­ti­fied neurobiomarkers—biological indi­ca­tors that are asso­ci­at­ed with cer­tain groups of patients, drug activ­i­ty, and ther­a­peu­tic efficacy.”

#8. Amy­loid-relat­ed imag­ing abnor­mal­i­ties (ARIA) found in approx­i­mate­ly 40% of patients tak­ing “Alzheimer’s drug” Aduhelm

Not good, yet com­plete­ly pre­dictable, and let’s remem­ber this is for a “treat­ment” cost­ing as much as $100,000/ year with exact­ly ZERO proven clin­i­cal ben­e­fit: “…The researchers found 425 cas­es in the com­bined adu­canum­ab group expe­ri­enced ARIA (41.3%), and ARIA-ede­ma was iden­ti­fied in 362 patients or 35.2%. Of them, 94 (26%) had symp­toms, such as headache, con­fu­sion, dizzi­ness and nau­sea. They found ARIA-micro­he­m­or­rhage and ARIA-super­fi­cial sidero­sis in 197 patients (19.1%) and 151 patients (14.7%), respectively.”

Final­ly, Let’s Thank our unique Human Brains and Minds with a few fam­i­ly-friend­ly riddles

Q: What does, “you must come and vis­it us some­time!” actu­al­ly mean?

 

Wish­ing you and yours a Hap­py & Healthy Hanukkah, Decem­ber and Christmas,

The Sharp­Brains Team

 

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Education & Lifelong Learning Tagged With: aducanumab, Aduhelm, Alzheimer's drug, Beacon Biosignals, Click Therapeutics, Cognitive Behavioral Therapy Monitoring, cognitive-bias, cognitive-testing, curiosity, Cybin, depression, digital therapeutics, FDA, insomnia, intellectual humility, Kernel Flow, machine-learning, neuroimaging, neuroplasticity, psychedelic, smoking cessation

Amyloid-related imaging abnormalities (ARIA) found in approximately 40% of patients taking “Alzheimer’s drug” Aduhelm

November 29, 2021 by SharpBrains

Study: Biogen’s Aduhelm Caused Brain Swelling in Over One-Third of Study Par­tic­i­pants (Bio­Space):

Atten­tion is being focused on a side effect of Biogen’s Alzheimer’s drug, Aduhelm (adu­canum­ab). Even before its con­tro­ver­sial approval on June 7, there were cas­es of amy­loid-relat­ed imag­ing abnor­mal­i­ties (ARIA‑E), or cere­bral ede­ma, observed in the tri­als. [Read more…] about Amy­loid-relat­ed imag­ing abnor­mal­i­ties (ARIA) found in approx­i­mate­ly 40% of patients tak­ing “Alzheimer’s drug” Aduhelm

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: aducanumab, Aduhelm, adverse side effects, Alzheimer's drug, amyloid-related imaging abnormalities, ARIA, ARIA-E, Biogen, cerebral edema, confusion, dizziness, early Alzheimer's disease, headache, nausea, side effects

On physical activity, neuroplasticity, depression, screen time, neuromodulation and more

October 29, 2021 by SharpBrains

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing this time eight sci­en­tif­ic reports and indus­try resources plus a few fun brain teasers.

#1. Study finds ulti­mate hack to pro­tect teen brains from harm­ful screen time: Exer­cise (and good role-mod­el­ing):

“Girls who spent less than an hour on screens and boys who spent less than 90 min­utes on screens were not neg­a­tive­ly impact­ed by it. But at high­er amounts of screen time, their life sat­is­fac­tion dropped significantly—they were less hap­py with their lives, and it got worse the more time they spent … (the) study also found that teens who got more reg­u­lar exer­cise had greater life sat­is­fac­tion and few­er phys­i­cal com­plaints for both gen­ders. Not only that, the effects were large­ly unre­lat­ed to how much time a teen spent on screens, so that if teens exer­cised more, it could poten­tial­ly undo the dam­age to their well-being that went along with even six or eight hours of screen time.”

#2. Stud­ies find grow­ing evi­dence link­ing weight, phys­i­cal activ­i­ty, neu­ro­plas­tic­i­ty and depres­sion:

‘Obe­si­ty and depres­sion are both major glob­al health chal­lenges, and our study pro­vides the most robust evi­dence to date that high­er BMI caus­es depres­sion,’ said lead author Jess O’Loughlin. ‘Under­stand­ing whether phys­i­cal or social fac­tors are respon­si­ble for this rela­tion­ship can help inform effec­tive strate­gies to improve men­tal health and wellbeing.’

#3. Dr. Judith Beck on the future of cog­ni­tive ther­a­py and psy­chother­a­py:

Let’s hope! — “I think Cog­ni­tive Behav­ioral Ther­a­py (CBT) will con­tin­ue to be adapt­ed for more prob­lems, diag­noses, and con­di­tions. We will train many kinds of care­givers, teach­ers, front-line work­ers, police, and even politicians.”

#4. Ratio­nal­i­ty doesn’t equal effi­cien­cy: Cell­phone data shows how we nav­i­gate cities:

“We dis­cov­ered that the most pre­dic­tive mod­el – rep­re­sent­ing the most com­mon mode of city nav­i­ga­tion – was not the quick­est path, but instead one that tried to min­i­mize the angle between the direc­tion a per­son is mov­ing and the line from the per­son to their des­ti­na­tion … Evo­lu­tion is a sto­ry of trade-offs, not opti­miza­tions, and the cog­ni­tive load of cal­cu­lat­ing a per­fect path rather than rely­ing on the sim­pler point­ing method might not be worth a few saved min­utes. After all, ear­ly humans had to pre­serve brain pow­er for dodg­ing stam­ped­ing ele­phants, just like peo­ple today might need to focus on avoid­ing aggres­sive SUVs.”

#5. Trend: Har­ness­ing dig­i­tal tech to improve men­tal health and well­ness:

“Designed with the help of Dutch aca­d­e­m­ic Isabela Granic … the game is cen­tred around an avatar who stays in bed for the day and aims to relax play­ers by using sooth­ing music, mut­ed colours and self-care prac­tices. Think med­i­ta­tive tasks such as word games and guid­ed breath­ing exer­cis­es. There’s no way to win, com­pete or binge – in fact, it delib­er­ate­ly starts to feel bor­ing after a few min­utes of play, which dis­in­cen­tivizes mind­less scrolling. #Self­Care was an instant hit, gar­ner­ing half a mil­lion down­loads in its first six weeks with­out any advertising…”

#6. Study: Per­son­al­ized, closed-loop neu­ro­mod­u­la­tion can (one day) become a “pace­mak­er for the brain”:

“What made this proof-of-prin­ci­ple tri­al suc­cess­ful was the dis­cov­ery of a neur­al bio­mark­er – a spe­cif­ic pat­tern of brain activ­i­ty that indi­cates the onset of symp­toms – and the team’s abil­i­ty to cus­tomize a new DBS device to respond only when it rec­og­nizes that pat­tern. The device then stim­u­lates a dif­fer­ent area of the brain cir­cuit, cre­at­ing on-demand, imme­di­ate ther­a­py that is unique to both the patient’s brain and the neur­al cir­cuit caus­ing her illness.”

#7. Six guide­lines to nav­i­gate the Aduhelm con­tro­ver­sy and (hope­ful­ly) help patients with Mild Cog­ni­tive Impair­ment and ear­ly-stage Alzheimer’s Dis­ease:

“After ini­tial­ly indi­cat­ing that Aduhelm could be pre­scribed to any­one with demen­tia, the Food and Drug Admin­is­tra­tion now spec­i­fies that the pre­scrip­tion drug be giv­en to indi­vid­u­als with mild cog­ni­tive impair­ment or ear­ly-stage Alzheimer’s, the groups in which the med­ica­tion was studied.
Yet this nar­row­er rec­om­men­da­tion rais­es ques­tions. What does a diag­no­sis of mild cog­ni­tive impair­ment mean? Is Aduhelm appro­pri­ate for all peo­ple with mild cog­ni­tive impair­ment, or only some? And who should decide which patients qual­i­fy for treat­ment: demen­tia spe­cial­ists or pri­ma­ry care physicians?”

#8. The Fed­er­al Trade Com­mis­sion (FTC) hard­ens data secu­ri­ty rules for health apps and devices:

“With data breach­es on the rise, the FTC is look­ing to make health apps more account­able for telling patients when their data has been exposed.”
And here are a few of our favorite brain teasers, in case you missed them…
  • Cel­e­brate Hal­loween with nine great riddles
  • Test your stress lev­el with this quick brain teaser
  • Where’s the baby?
  • Learn about cog­ni­tion and men­tal self-rotation

 

Wish­ing you and yours a sweet Hal­loween and a healthy month of November,

The Sharp­Brains Team

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Education & Lifelong Learning, Peak Performance, SharpBrains Monthly eNewsletter, Technology & Innovation Tagged With: Aduhelm, Brain Teasers, CBT, cognitive load, cognitive-behavioral-therapy, cognitive-therapy, depression, digital health, digital tech, early-stage Alzheimer’s, exercise, FTC, mild-cognitive-impairment, neural biomarker, neural circuit, neuromodulation, neuroplasticity, obesity, pacemaker for the brain, Physical-activity, Psychotherapy, screen time, weight

Six guidelines to navigate the Aduhelm controversy and (hopefully) help patients with Mild Cognitive Impairment and early-stage Alzheimer’s Disease

October 13, 2021 by Kaiser Health News

The approval of a con­tro­ver­sial new drug for Alzheimer’s dis­ease, Aduhelm, is shin­ing a spot­light on mild cog­ni­tive impair­ment — prob­lems with mem­o­ry, atten­tion, lan­guage or oth­er cog­ni­tive tasks that exceed changes expect­ed with nor­mal aging.

After ini­tial­ly indi­cat­ing that Aduhelm could be pre­scribed to any­one with demen­tia, the Food and Drug Admin­is­tra­tion now spec­i­fies that the pre­scrip­tion drug be giv­en to indi­vid­u­als with mild cog­ni­tive impair­ment or ear­ly-stage Alzheimer’s, the groups in which the med­ica­tion was studied.

Yet this nar­row­er rec­om­men­da­tion rais­es ques­tions. What does a diag­no­sis of mild cog­ni­tive impair­ment mean? Is Aduhelm appro­pri­ate for all peo­ple with mild cog­ni­tive impair­ment, or only some? And who should decide which patients qual­i­fy for treat­ment: demen­tia spe­cial­ists or pri­ma­ry care physi­cians? [Read more…] about Six guide­lines to nav­i­gate the Aduhelm con­tro­ver­sy and (hope­ful­ly) help patients with Mild Cog­ni­tive Impair­ment and ear­ly-stage Alzheimer’s Disease

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: Aduhelm, Alzheimer’s Disease, attention-problems, brain bleeding, brain swelling, cognitive problems, dementia, dementia specialists, early-stage Alzheimer’s, Food and Drug Administration, language problems, memory problems, mild-cognitive-impairment, neuropsychological, neuropsychological-tests, normal cognition, primary care physicians, tests

Welcome to the Ultimate Neuroscience Lab: Your Smartphone

September 30, 2021 by SharpBrains

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing this time six sci­en­tif­ic reports and indus­try resources plus a fun illusion.

#1. Top 10 Men­tal Health Inno­va­tions to Watch: Spe­cial SciAm/ WEF report

Hop­ing you enjoy the great series over at Sci­en­tif­ic Amer­i­can and espe­cial­ly #7, titled Wel­come to the Ulti­mate Neu­ro­science Lab: Your Smart­phone, by Emory neu­roethi­cist Karen Rom­melfanger and our very own Álvaro Fer­nán­dez Ibáñez.

#2. Five thoughts to think about when think­ing about the speed of thought

The time it takes for all thoughts to occur is ulti­mate­ly shaped by the char­ac­ter­is­tics of the neu­rons and the net­works involved. Many things influ­ence the speed at which infor­ma­tion flows through the sys­tem, but three key fac­tors are: dis­tance, myeli­na­tion, complexity,

#3. Study: Self-guid­ed sleep app Sleepio, com­bined with stan­dard care for depres­sion and anx­i­ety, deliv­ers bet­ter out­comes than stan­dard care alone

“This eval­u­a­tion revealed sig­nif­i­cant val­ue in intro­duc­ing an evi­dence-based dig­i­tal sleep inter­ven­tion at scale with­in a clin­i­cal men­tal health ser­vice,” researchers from Big Health and Oxford Health NHS Foun­da­tion Trust conclude.

#4. On uncer­tain­ty, stress, emo­tion reg­u­la­tion, and carpe diem

“These find­ings from three stud­ies with diverse sam­ples and method­olo­gies under­score an upside to the specter of uncer­tain­ty: it can cause peo­ple to savor the pos­i­tives of the present.”

#5. Study finds ADHD is asso­ci­at­ed with dementia

“Specif­i­cal­ly, par­ents of an ADHD child have a 34% high­er risk of demen­tia and 55% high­er risk of Alzheimer’s, the results showed. Grand­par­ents have about an 11% increased risk of either condition.”

#6. Study: Few­er than 1% of geri­atric patients with cog­ni­tive com­plaints met Aduhelm research tri­al cri­te­ria. What can we expect about its real-world safety?

As the researchers point out, “It is thus clear how the result­ing gap between the research and “real world” fields is mas­sive.” We do have the impres­sion that the Aduhelm FDA saga is far from over.

#7. Quick brain teas­er: What do you see? And, can you unsee it?

Have a minute? Give it a try 🙂

 

Wish­ing you and yours a hap­py and healthy month of October,

The Sharp­Brains Team

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: adhd, Aduhelm, brain-teaser, cognitive, cognitive complaints, dementia, emotion regulation, lifelong mental health, lifelong-brain-health, myelination, Neurons, neuroscience lab, quick brain teaser, Sleepio, smartphone

Study: Fewer than 1% of geriatric patients with cognitive complaints met Aduhelm research trial criteria. What can we expect about its real-world safety?

September 7, 2021 by SharpBrains

Bio­gen’s Aduhelm label far exceeds clin­i­cal tri­al pop­u­la­tion, study says. That could bring real-world sur­pris­es (Fierce Pharma):

While the chat­ter sur­round­ing Biogen’s con­tro­ver­sial Alzheimer’s med Aduhelm has large­ly been cen­tered on a piv­otal Medicare reim­burse­ment deci­sion as of late, ana­lysts are point­ing to one new study that sug­gests there may be “room for sur­pris­es” when it comes to the treatment’s safe­ty. [Read more…] about Study: Few­er than 1% of geri­atric patients with cog­ni­tive com­plaints met Aduhelm research tri­al cri­te­ria. What can we expect about its real-world safety?

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: aducanumab, Aduhelm, Alzheimer's med, American Geriatrics Society, Biogen, cognitive, cognitive complaints, FDA, Medicare reimbursement, undetected side effects

Next Page »

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,620 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2022 SharpBrains. All Rights Reserved - Privacy Policy